Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Segment Information (Details)

v3.22.0.1
Segment Information (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2021
USD ($)
segment
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Segment Reporting Information [Line Items]      
Number of operating segments | segment 2    
Net revenue:      
Total net revenue $ 484,329 $ 444,448 $ 408,830
Cost of revenue:      
Cost of revenue 297,269 258,555 211,994
Gross profit:      
Gross Profit 187,060 185,893 196,836
Operating expenses:      
General and administrative 221,347 143,794 127,993
Research and development 21,873 8,229 8,487
Sales and marketing 62,594 47,862 47,350
Total operating expenses 305,814 199,885 183,830
(LOSS) INCOME FROM OPERATIONS (118,754) (13,992) 13,006
Interest expense, net 5,082 7,019 3,713
Other expense (income), net 499 (7,906) 4,630
Gain on investment in and loan receivable from non-consolidated affiliate, net (109,260) (3,955) 0
Loss on debt extinguishment 0 1,400 1,018
Loss on termination of cash flow hedge 0 3,506 0
(Loss) income before taxes (15,075) (14,056) 3,645
Income tax benefit (6,728) (18,228) (4,361)
NET (LOSS) INCOME (8,347) 4,172 8,006
Clinical Services      
Net revenue:      
Total net revenue 404,172 382,337 361,161
Cost of revenue:      
Cost of revenue 244,360 215,529 185,612
Gross profit:      
Gross Profit 159,812 166,808 175,549
Clinical Services | Amortization of acquired developed technology intangible assets      
Cost of revenue:      
Cost of revenue 9,200    
Clinical Services | Write Off For COVID-19 PCR Testing Inventory      
Cost of revenue:      
Cost of revenue 5,300    
Pharma Services      
Net revenue:      
Total net revenue 80,157 62,111 47,669
Cost of revenue:      
Cost of revenue 52,909 43,026 26,382
Gross profit:      
Gross Profit 27,248 $ 19,085 $ 21,287
Pharma Services | Amortization of acquired developed technology intangible assets      
Cost of revenue:      
Cost of revenue $ 1,200